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ABSTRACT
The purpose of this study was to determine long-term outcome of unrelated donor nonmyeloablative hema-
topoietic cell transplantation (HCT) in patients with poor-risk multiple myeloma. A total of 24 patients were
enrolled; 17 patients (71%) had chemotherapy-refractory disease, and 14 (58%) experienced disease relapse or
progression after previous autologous transplantation. Thirteen patients underwent planned autologous trans-
plantation followed 43–135 days later with unrelated transplantation, whereas 11 proceeded directly to
unrelated transplantation. All 24 patients were treated with fludarabine (90 mg/m2) and 2 Gy of total body
irradiation before HLA-matched unrelated peripheral blood stem cell transplantation. Postgrafting immuno-
suppression consisted of cyclosporine and mycophenolate mofetil. The median follow-up was 3 years after
allografting. One patient experienced nonfatal graft rejection. The incidences of acute grades II and III and
chronic graft-versus-host disease were 54%, 13%, and 75%, respectively. The 3-year nonrelapse mortality
(NRM) was 21%. Complete responses were observed in 10 patients (42%); partial responses, in 4 (17%). At 3
years, overall survival (OS) and progression-free survival (PFS) rates were 61% and 33%, respectively. Patients
receiving tandem autologous-unrelated transplantation had superior OS and PFS (77% and 51%) compared
with patients proceeding directly to unrelated donor transplantation (44% and 11%) (PFS P value  .03). In
summary, for patients with poor-risk, relapsed, or refractory multiple myeloma, cytoreductive autologous
HCT followed by nonmyeloablative conditioning and unrelated HCT is an effective treatment approach, with
low NRM, high complete remission rates, and prolonged disease-free survival.
© 2007 American Society for Blood and Marrow Transplantation
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High-dose conditioning and autologous hemato-
oietic cell transplantation (HCT) is effective in pro-
onging survival for patients with multiple myeloma;
onetheless, nearly all patients eventually relapse
1-6]. Long-term remissions and possibly cures have
een described with allogeneic HCT after conven-
ional high-dose conditioning regimens [7-9]. How-
ver, high-dose conditioning regimens for allogeneic
CT are associated with a 40%–50% risk of early
onrelapse mortality (NRM) [7-10]. Nonmyeloabla-
ive conditioning regimens for allogeneic HCT have
ramatically reduced early transplantation-related
ortality (TRM) and sparked interest in applying this
reatment to multiple myeloma [11-21]. One particu-
arly promising treatment has been to combine the
ytoreductive beneﬁt of high-dose melphalan and au-
ologous “rescue,” followed by the graft-versus-tumor
GVT) effects of nonmyeloablative allografts, initially
rom HLA-matched siblings [22,23]. For patients who
ack HLA-matched siblings, unrelated donor HCT is
n important alternative [12]. Several reports have
escribed reduced-intensity conditioning with unre-
ated donor HCT; however, the number of patients
ith multiple myeloma studied and the duration of
ollow-up have been limited to date [12,20,23-31].
In an earlier study [12], we showed that a nonmy-
loablative conditioning regimen consisting of ﬂu-
arabine 30 mg/m2/day given on 3 consecutive days
nd 2 Gy of total body irradiation (TBI) combined
ith postgrafting immunosuppression with cyclospor-
ne (CSP) and mycophenolate mofetil (MMF) allowed
table engraftment of unrelated hematopoietic cells in
atients with various hematologic malignancies. In the
resent article, we describe the clinical outcomes of 24
atients with advanced multiple myeloma who re-
eived grafts from HLA-matched unrelated donors
ith a median follow-up of 3 years. Thirteen of the 24
atients had planned autologous HCT followed by
nrelated HCT, whereas 11 proceeded directly to
nrelated HCT.
ATIENTS AND METHODS
ligibility Criteria
A total of 24 patients with multiple myeloma were
nrolled in 3 sequential phase I/II multi-institutional
red Hutchinson Cancer Research Centers for unre-
ated HCT protocols for hematologic malignancies
etween May 16, 2000, and November 23, 2004 [32].
he patients were treated at 9 centers. Each patient
igned a consent form approved by the local institu-
ional review board. Inclusion criteria were the diag-
osis of multiple myeloma, high risk for NRM from
ailure of previous treatment with high-dose autolo- bous HCT or preexisting comorbidities, and failure of
or more front-line therapies [12].
LA Typing and Matching
A total of 23 patient–donor pairs had HLA-allele
evel typing performed for 10 HLA alleles (HLA-A,
B, -C, -DRB1, and -DQB1) [33]. Patient 5 did not
ave high-resolution typing for all 10 HLA alleles.
wenty patients were matched with their donors for
0 of 10 HLA alleles, and 3 patients (patients 4, 9, and
4) had single HLA-C allele-level mismatches.
eripheral Blood Stem Cell Mobilization/
igh-Dose Melphalan/Autologous HCT
Thirteen patients underwent planned high-dose
utologous HCT before unrelated donor HCT. Un-
ess previously cryopreserved, peripheral blood stem
ells (PBSCs) were collected and cryopreserved after
yclophosphamide (4 g/m2) and Mensa (4 gtm2) given
n day 1, etopside (200 mgtm2/day), on days 1–3;
examethasone 40 mg/day on days 1–4, and granulo-
yte colony-stimulating factor (G-CSF; 10 g/kg/day)
ere given from day 4 until collection [34]. Melphalan
200 mg/m2) was given  30 days after mobilization
hemotherapy. Autologous PBSCs were infused 48
ours after melphalan [22]. The median CD34 cell
umber was 6.1  106/kg (range, 3.5–8.8  106/kg).
atients proceeded to allografting after recovery from
utologous HCT.
Eleven patients proceeded directly to unrelated
onor HCT because of lack of availability of cryopre-
erved PBSCs, physician preference, or inability to
btain medical insurance coverage for a planned tan-
em autologous unrelated HCT.
onmyeloablative Conditioning Regimen and
osttransplantation Immunosuppression
Conditioning included 3 doses of ﬂudarabine 30
g/m2/day on days 4 to 2, followed by 2-Gy TBI
t rates of 0.07–0.10 Gy/min from linear accelerators
n day 0. Postgrafting immunosuppression included
SP and MMF, as described previously [12,32]. Pa-
ients 1–7 received MMF 15 mg/kg every 12 hours,
nd patients 8–24 received MMF 15 mg/kg every 8
ours. Grading and treatment of graft-versus-host dis-
ase (GVHD) was done as described previously
12,35].
ollection of Unrelated PBSCs
nd Supportive Care
All patients received fresh G-CSF–mobilized
BSCs from unrelated donors coordinated through
nrelated donor registry protocols [12]. National
arrow Donor Program donors received G-CSF 10
g/kg/day on days5 through1. The median num-
er of CD34 cells infused was 8.87  106/kg (range,
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Nonmyeloablative Unrelated Donor Transplantation for Myeloma 425.1–23.1  106/kg). Antimicrobial and cytomegalovi-
us prophylaxis and blood product support were given
s described previously [12].
nalyses of Risk Factors, Disease Responses,
nd Toxicities
Cytogenetic abnormalities were assessed at time of
iagnosis in 14 patients using conventional karyotype
-banding (Table 1). Donor engraftment was con-
rmed by chimerism analyses [36]. Patients were eval-
ated for disease during the 2-week interval before
utologous and/or unrelated HCT to estimate the
aseline levels of disease activity. Disease responses
ere assessed using the American Bone Marrow
ransplant Registry criteria [37]. Patients were con-
idered refractory to chemotherapy if they had less
han a partial response (PR) to the last regimen ad-
inistered before study entry. Restaging studies were
erformed at 28, 56, and 84 days and 6 months after
nrelated HCT, and at 6-month intervals thereafter.
Medical comorbidities were evaluated using a
odiﬁed Charleson comorbidity index (CCI) [15].
retransplantation comorbid diseases included myo-
ardial infarction, congestive heart failure, peripheral
ascular or cerebrovascular disease, hepatic disease,
iabetes (with end-organ damage), pulmonary disease
moderate–severe dyspnea on exertion), and serum
reatinine level  2.0 mg/dL [15].
The NCI Common Terminology Criteria for Ad-
erse Events (CTCAE) version 3 grading system (avail-
ble at http://ctep.cancer.gov/reporting/ctc.html) was
sed to evaluate toxicity during the ﬁrst 100 days after
llografting. All toxicities were graded and reported.
tatistical Methods
OS and PFS were estimated by the Kaplan-Meier
ethod. Cumulative incidence estimates were calcu-
ated for acute and chronic GVHD, relapse, relapse-
elated mortality, and NRM. Deaths were treated as
ompeting events in analyses of graft rejection,
VHD, and disease progression. Disease progression
nd NRM were the components of PFS and were
reated as competing events. Fisher’s exact test was
sed to compare 2 groups. All P values were derived
rom likelihood ratio statistics and were 2-sided.
omparisons of survival and PFS were based on log-
ank tests. Follow-up was as of April 1, 2006.
ESULTS
atient Characteristics
Table 1 summarizes the clinical features of the 24
atients enrolled in the study. All patients had ad-
anced disease at time of study enrollment. The me-
ian time from disease diagnosis to unrelated donor
CT was 25 months (range, 8–130 months). All pa- 4ients had received therapy for myeloma. Twenty-
hree (96%) were beyond ﬁrst complete remission
CR1) or never achieved CR1 despite multiple distinct
hemotherapy regimens (median, 4.5 regimens; range,
–10). Twenty-three (96%) had received vincristine,
driamycin, and dexamethasone for a median of 5
ycles (range, 1–11) [38], and 14 (58%) had received
halidomide-dexamethasone [39]. One patient had re-
eived bortezomib, with disease progression before
tudy entry. Fourteen (58%) had relapsed/progressed
fter previous high-dose autologous HCT at a median
f 10 months before study enrollment (range, 3–40
onths). Seventeen (71%) had disease that was refrac-
ory to their most recent chemotherapy regimen, 5
21%) had PR, and 2 (8%) had CR.
lanned Autologous HCT
Thirteen patients received planned autologous
CT for cytoreduction a median of 75 days before
nrelated HCT (range, 43–135 days). After melphalan
reatment, all 13 patients recovered hematopoiesis;
he median duration with neutrophils  500/L was
.5 days (range, 7–14 days), and the median duration
ith platelets  20,000/L was 2.5 days (range, 0–9
ays).
Five patients had relapsed after previous autolo-
ous HCT. The disease responses after planned au-
ologous HCT were CR in 1 patient, PR in 7 patients,
nd stable disease in 5 patients.
nrelated Donor Engraftment Kinetics
nd Chimerism
During the ﬁrst 100 days after unrelated HCT,
he patients had a median duration of neutropenia of
days (range, 0–80) days. Transient severe thrombo-
ytopenia ( 20  103 platelets/L) occurred in 6
atients (25%). Transfusion requirements were a me-
ian of 7 units of red blood cells (range, 0–34 units)
nd 0 units of platelets (range, 0–45 units).
Median levels of peripheral blood CD3, CD33,
nd whole marrow donor chimerism at day 28 were
4%, 99%, and 98%, respectively. One patient (4%)
xperienced nonfatal graft rejection by day 56, with
ecovery of autologous hematopoiesis. All surviving
atients with engraftment eventually achieved 100%
onor chimerism.
oxicity
The regimen of ﬂudarabine and 2-Gy TBI was
ell tolerated. No patient experienced mucositis, se-
ere diarrhea, or veno-occlusive disease of the liver
ttributable to the conditioning regimen. For the ﬁrst
00 days posttransplantation, the median number of
npatient hospital days was 13.5 (range, 0–57). Grade
hematologic toxicity occurred in 75% of patients,
Table 1. Pretransplantation Patient Characteristics
Transplant
Patient
(PIN)
Age
(Years)/
Sex
Known
Cytogentic
Abnormality
Number of
Regimens Before
Auto/Allo or
URD HCT
Prior Local
Radiotherapy
Months From
Diagnosis to
URD HCT
Failure of
Prior Auto
HCT*
Disease
Stage/Type
at HCT
2
Micro-globulin
at HCT
CCI
Score
Response to
Last Preceding
Chemotherapy
Line
Planned tandem auto/
unrelated HCT
3 44/F NE 4 No 8 No IIA IgG 1.7 0 Refractory
4 49/M NE 5 No 14 No IIIA IgG 2.0 0 Refractory
7 53/M  13, complex 2 No 10 No IIIB  15.3 2 Refractory
14 49/M NE 2 No 14 No IIIA IgG 1.5 0 Refractory
19 59/M Complex 2 No 11 No IIIA IgG 2.4 1 Refractory
20 51/M  13, complex 2 No 15 No IIIA IgA 1.5 0 PR
21 35/F  13, complex 6 No 28 No IIIA IgA 1.7 0 Refractory
24 51/F None 2 Yes 8 No IIIA IgG 1.3 0 PR
6 31/M NE 6 Yes 77 Yes IIIA IgA 3.3 0 PR
15 53/M Complex 6 Yes 57 Yes IIIA IgG 2.6 1 Refractory
16 61/M  13, complex 10 Yes 44 Yes IIIB IgG 2.1 6 Refractory
17 29/M  13, complex 4 Yes 13 Yes IIIB IgA 2.7 1 Refractory
23 64/M None 7 No 43 Yes IIIB  4.5 3 Refractory
Proceeded directly to
unrelated HCT
1 41/M t 11;14 5 No 30 No IIIA IgG 4.1 0 Refractory
18 39/M NE 3 No 17 No* IIIA  2.2 0 CR
2 61/M None 5 Yes 21 Yes IIIA IgG 1.6 0 Refractory
5 54/M t 1;4 4 No 22 Yes IIA IgG 3.2 0 Refractory
8 53/F NE 8 Yes 130 Yes IIIA IgG 1.3 0 Refractory
9 57/M Complex 6 No 55 Yes IIIA IgG 3.9 1 Refractory
10 66/M NE 6 Yes 108 Yes IIIA igG 3.5 0 Refractory
11 38/M NE 4 No 54 Yes IIA IgG 2.5 0 PR
12 61/M  13, complex 4 No 29 Yes IIIA igA 1.3 0 CR
13 53/M NE 4 No 12 Yes IIIA IgG 5.1 0 Refractory
22 52/F NE 8 No 80 Yes IIA IgG 1.7 0 PR
Patients in shaded regions had a history of disease relapse/progression after previous autologous hematopoietic cell transplantation (HCT). Dx, diagnosis; CCI, modiﬁed Charleson comorbidity
index [15].
PR indicates partial response; CR, complete response; refractory, no CR or PR to last preceding chemotherapy line; PIN, patient identiﬁcation number; PINs 1–24 assigned in chronological order by
day of URD HCT.
*Patient 18 received an autologous HCT 11 months before proceeding to unrelated HCT.
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Nonmyeloablative Unrelated Donor Transplantation for Myeloma 427rimarily because of transient neutropenia before do-
or engraftment.
Table 2 summarizes the signiﬁcant nonhemato-
ogic toxicity for days 0–100. The day 100 NRM was
%. One patient with preexisting congestive heart
ailure died of multiorgan failure. One patient (4%)
eveloped grade 4 pulmonary toxicity, and 16 patients
67%) developed at least 1 grade 3 toxicity.
VHD
Acute GVHD developed in 16 patients (67%) at a
edian of 33 days (range, 7–119 days) (Table 2, Fig-
re 1A). Thirteen patients (54%) had grade II acute
VHD (aGVHD), involving primarily the skin (n 
2) and the gut (n  6). All 13 patients responded
romptly to treatment with prednisone 1–2 mg/kg/
ay. Three patients with grade III acute GVHD sub-
equently died, at 57, 153, and 215 days. There were
o cases of grade IV GVHD. The cumulative inci-
ence of chronic extensive GVHD (cGVHD) was
5% (Table 2, Figure 1B). The median day of onset of
GVHD was 132 days (range, 85–455 days).
RM
NRM was 21% at 3 years (Figure 1C). A total of
patients died from nonrelapse causes at a median of
months (range, 2–37 months), 4 with stable disease
nd 2 in CR. Four patients died from complications
ssociated with GVHD and opportunistic infections,
esulting from disseminated Aspergillus, parainﬂuen-
a-3 virus, Klebsiella sp, and methicillin-resistant
taphylococcus Aureus bacteremia. One patient died of
ongestive heart failure (see Toxicity), and 1 patient
ied of necrotizing pancreatitis.
isease Responses
Table 2 summarizes the disease responses for each
atient. Ten patients (42%) achieved or remained in CR
nd 4 (17%) achieved PR, for an overall response rate of
8%. The best disease responses were observed in the 13
atients who underwent tandem autologous-unrelated
CT (P  .01). In this group, 7 had CR and 3 had PR,
or an overall response rate of 77%. In contrast, only 2
atients (18%) who proceeded directly to unrelated
CT had measurable disease response.
No signiﬁcant temporal association was found be-
ween onset of extensive cGVHD and subsequent
isease responses (P .39). No patient received donor
ymphocyte infusion.
S and PFS
The median follow-up of surviving patients from
he time of allografting was 3 years (range, 1.2–5.5
ears). For all 24 patients, the 3-year estimated OS
as 61%, and the PFS was 33% (Figure 2A).The patients who underwent tandem autologous- anrelated HCT had signiﬁcantly better PFS com-
ared with those who proceeded directly to unrelated
onor HCT (P  .03). The difference in OS between
he 2 groups was not statistically signiﬁcant (P  .30).
n the 13 patients who underwent tandem autologous-
nrelated HCT, the estimated 3-year OS was 77%,
nd the PFS was 51% (Figure 2B). In the 11 patients
ho proceeded directly to unrelated donor HCT, the
stimated 3-year OS was 44% and the PFS was 11%
Figure 2C).
isk Factors for Survival
Risk factors associated with poorer OS included
igniﬁcant medical comorbidities before HCT, che-
otherapy-refractory disease, and relapse/progression
fter previous autologous HCT. Survival was worse in
he 7 patients with modiﬁed CCI scores 1 compared
ith those with scores of 0 (P  .03) (Figure 3A). All
patients with CCI scores  2 died from nonrelapse
auses. In the 13 patients who underwent tandem
utologous-unrelated HCT, CCI scores 1 were also
ssociated with worse OS (P  .01).
All of the 7 patients who were in PR or CR at the
ime of study enrollment were alive with follow-up to
years. In contrast, survival at 3 years for the 17
atients with refractory disease was 45% (P  .02)
Figure 3B).
The 14 patients who experienced relapse or dis-
ase progression after a previous autologous HCT
referred to as “failure of previous autologous HCT”)
ad worse OS and PFS than those who did not have
revious HCT or failure of previous autologous HCT
P  .10 and .05, respectively; Figure 3C). The pa-
ients who experienced failure of previous autologous
CT had an OS of 42% and a PFS of 17% 3 years
fter unrelated HCT. In these 14 patients, there was
o difference in OS or PFS between proceeding di-
ectly to unrelated HCT or to tandem autologous-
nrelated HCT (P  .58 and .98, respectively).
The presence of deletion chromosome 13 had no
pparent effect on outcome, but there were few evalu-
ble patients. Other factors, such as duration of dis-
ase and 2 microglobulin, also did not inﬂuence
urvival.
ISCUSSION
The present multicenter study of patients with
dvanced, poor-risk multiple myeloma demonstrates
hat a nonmyeloablative conditioning regimen com-
rising ﬂudarabine and 2-Gy TBI followed by unre-
ated donor PBSC transplantation is effective treat-
ent. Tandem autologous-unrelated HCT provided
n OS of 77% and a PFS of 51% 3 years after al-
ografting. These results are superior to those
chieved in patients who proceeded directly to unre-
Table 2. Outcomes After Transplantation
Transplant
Prior Auto
HCT
Patient
(PIN)
% Donor
CD3 Cells,
Day 28
Acute GVHD Chronic GVHD
Recent
IST
Toxicity
Grade,
Maximum,
Day 0–100
Disease
Response
to Planned
Auto HCT
Survival After
URD HCT (Days)
[Cause of Death]
Disease Outcome
after URD HCT
[Month of CR/PR/
PD/Relapse]
Grade,
Organ
Day of
Onset Extensive
Day of
Onset
Planned tandem auto/
unrelated HCT
No 3 85–90 II S 7 Yes 85 Taper 3 PR >2030 CR [42]
No 4 100 0 — Yes 190 No 2 PR >1829 CR [12]¡ Rel [27]
No 7 95 II S 59 Yes 89 — 2 PR 1105† [NRM, GVHD/OI] CR [19]
No 14 93 II S,G 9 Yes 175 Taper 3 SD >1323 SD
No 19 85 0 — Yes 420 Yes 3 CR >765 CCR
No 20 77 II S 75 No — No 3 PR >546 PR [6]
No 21 70 0 — No — No 2 SD >615 PR [12]
No 24 95 II S 47 Yes 127 Taper 2 PR >428 PR [6]
Failure of prior
auto HCT
6 100 0 — Yes 455 Taper 3 PR >1498 CR [12]
15 100 II S,G 14 Yes 93 Taper 3 PR >1200 CR [3]¡Rel [35]
16 95 III G 44 No — — 5 SD 57† [NRM, MOF/OI] SD
17 85–90 II G 21 No — — 3 SD 106† [PD] PD [2]
23 100 III S,G 119 Yes 190 — 3 PR 215† [NRM, GVHD/OI] CR [6]
Proceeded directly to
unrelated HCT
No 1 80–90 II S 32 No — — 3 — 89† [PD] PD [2]
Yes 18 95 0 — Yes 235 Taper 2 — >1080 CCR ¡Rel [22]
Failure of prior
auto HCT
2 95–99 II S 29 Yes 100 — 4 — 271† [PD] PD [4]
5 100 II S 48 No — — 3 — 1030† [PD] PD [25]
8 93 II S,G 28 Yes 92 — 3 — 166† [NRM, MOF/OI] SD
9 100 III S,G,L 10 Yes 132 — 3 — 153† [NRM, GVHD/OI] SD
10 90–95 II S,G 37 Yes 123 — 3 — 290† [NRM, GVHD/OI] SD
11 5 0 — No — N/A 3 — >1124* SD*
12 95–99 II S,G 34 Yes 84 No 3 — >1356 CCR ¡Rel [6]
13 92 0 — Yes 418 Taper 3 — >1398 PR [12]
22 69 0 — No — No 2 — >541 CR [6] ¡Rel [17]
Patients in the shaded region had a history of relapse/progression after previous autologous HCT.
S indicates skin; G, gut; L, liver; URD, unrelated donor; NRM, nonrelapse mortality; OI, opportunistic infection; MOF, multiorgan failure; CR, complete response; CCR, continuous CR; PR, partial
response; PD, progressive disease; Rel, relapse; SD, stable disease; N/A, not applicable; Recent IST, immune suppressive therapy within 4 months of last contact date for surviving patients. PIN,
patient identiﬁcation number, assigned chronologically by day of URD HCT.
*Patient 11 rejected the unrelated donor graft and proceeded to second nonmyeloablative unrelated HCT at 11.5 months. He engrafted and achieved CR at 24 months.
Summary of day 0–100 toxicity: Patient 16 died of multiorgan failure on day 57. Patient 2 developed grade 4 pneumonitis requiring brief intubation and mechanical ventilation. Sixteen patients (67%)
developed at least one grade 3 toxicity including bacteremia or fever of unknown origin treated with antibiotics (n  11), pulmonary inﬁltrates/pneumonitis (n  6), transient hyperbilirubinemia
(n  5), gastrointestinal nausea/vomiting (n  4), cardiac arrhythmia or hypertension (n  2), hemorrhage (n  2), musculoskeletal pain (n  1), and renal/metabolic toxicity (n  1).
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Nonmyeloablative Unrelated Donor Transplantation for Myeloma 429ated HCT (ie, 3-year OS of 44% and PFS of 11%).
lthough the difference in results was likely related to
atient selection, the data do suggest that tandem
utologous-unrelated HCT is the optimal treatment
pproach. However, the relatively small number of
atients evaluated limits the strength of this conclu-
ion.
Despite having poor-risk disease and advanced
ge, the patients exhibited good tolerance of nonmy-
loablative conditioning with ﬂudarabine 90 mg/m2
nd 2-Gy TBI. Grade IV–V nonhematologic toxicities
ithin the ﬁrst 100 days were infrequent compared
ith those associated with intensive conditioning reg-
mens in younger patients [7-10]. Consistent with re-
igure 1. Cumulative incidence of GVHD after unrelated HCT
n  24). (A) Acute GVHD: 67% all grades of GVHD, 54% grade
I, and 13% grade III GVHD by day 120. (B) Chronic extensive
VHD, 75% incidence at 3 years. (C) NRM, 21% at 3 years.ent reports, patients with signiﬁcant pretransplanta- 1ion medical comorbidities were at increased risk for
RM [15]; however, NRM was low in patients with
CI scores  2.
Other prognostic risk factors for worse OS in-
luded myeloma progression/relapse after previous
utologous HCT and chemotherapy-refractory dis-
ase. Kröger et al. [30] reported that patients who
xperienced progression/relapse after previous autol-
gous HCT were at high risk for TRM and disease
elapse after ﬂudarabine/melphalan conditioning,
ith a 2-year PFS  10%. In the current study,
atients with disease progression/relapse after a pre-
ious autologous HCT had a 2-year PFS of 34%.
Despite the advanced stage of multiple myeloma
nd the high proportions of patients with chemother-
igure 2. OS (solid line) and PFS (dotted line) after nonmyeloab-
ative conditioning and unrelated HCT for (A) all patients studied
n  24), (B) recipients of tandem autologous-unrelated HCT (n 
3), and (C) patients proceeding directly to unrelated HCT (n 
1).
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G. E. Georges et al.430py-refractory disease and comorbidities, our current
esults compare favorably with those reported previ-
usly by others [24-26,29]. Moreover, the 3-year me-
ian follow-up in our study allows for better assess-
ent of the long-term efﬁcacy of unrelated donor
CT compared with earlier reports. An EBMT reg-
stry analysis of 229 patients with multiple myeloma
reated with various reduced-intensity conditioning
egimens reported that 32 patients received HLA-
atched unrelated grafts [31]; the 1-year TRM was
0%, and the 3-year OS was 17%. The authors con-
luded that those patients who were heavily pretreated
igure 3. Risk factors for OS after nonmyeloablative conditioning
nd unrelated HCT for all 24 patients. (A) CCI score [15] of 0 (solid
ine, n  17), or  1 (dashed line, n  7) (P  .03). (B) Disease-
ensitive (solid line, n 7) or refractory (dashed line, n 17) to the
ost recent chemotherapy regimen (P  .02). (C) Failure of pre-
ious autologous HCT (dashed line, n  14) or no previous/no
ailure of previous autologous HCT (solid line, n  10) (P  .10).r who had chemotherapy-resistant disease did not peneﬁt from allogeneic HCT. Our results do not
upport their conclusion. Our patients with chemo-
herapy-refractory disease who underwent a tandem
utologous-unrelated HCT had a 3–year OS of 70%,
nd those who experienced progression/relapse after
revious autologous HCT had a 3-year OS of 40%.
Although we used high-resolution methods to
dentify HLA-matched unrelated donors, the cumula-
ive incidence of cGVHD was 75% at 3 years. Most of
he patients with cGVHD tolerated a tapered immu-
osuppressive therapy; however, some required pro-
onged therapy. Perhaps owing to the small number of
atients studied, the cytoreduction provided by the
utologous HCT, and the relatively high incidence of
GVHD, we found no signiﬁcant association between
GVHD and disease response. However, in a larger
ohort of patients with various hematologic malignan-
ies who underwent nonmyeloablative allogeneic
CT, those with cGVHD exhibited improved OS
nd PFS [40]. The sustained PFS seen in our study is
ikely related to the graft-versus-myeloma beneﬁt of
GVHD. Longer follow-up is needed to determine
hether durable remission of myeloma can be
chieved.
For those patients who experienced relapse/
rogression after previous autologous HCT, our study
ound no beneﬁt of tandem autologous-unrelated
CT as opposed to proceeding directly to unrelated
CT. However, because a second autologous HCT
an provide effective cytoreduction with low NRM
8,41], selected patients who experience failure of pre-
ious autologous HCT possibly could beneﬁt from
andem autologous-unrelated HCT.
The recent development of the drugs bortezomib
nd lenalidomide offers patients with multiple my-
loma the possibility of more effective cytoreduction
efore transplantation [42-44]. Despite the introduc-
ion of novel agents for myeloma, the problem of
isease relapse after chemotherapy persists. Allogeneic
CT, with the immune-mediated GVT effect, offers
he possibility of deﬁnitive curative therapy. However,
GVHD remains a cause of signiﬁcant morbidity, and
uture progress will require limiting the graft-versus-
ost reaction to myeloma-speciﬁc antigens. Because of
he relatively limited toxicity of bortezomib and lena-
idomide, patients who experience disease relapse after
nrelated HCT may beneﬁt from therapy with these
gents to augment the GVT effect of the allograft
45].
In conclusion, our ﬁndings support the broader
pplication of tandem autologous-unrelated HCT for
atients with multiple myeloma. The low NRM ob-
erved in patients with low CCI scores and chemo-
herapy-sensitive disease suggests that these patients
ould beneﬁt from referral for nonmyeloablative un-
elated HCT at an earlier disease stage. Patients with
oor-risk but chemotherapy-sensitive disease, includ-
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lbumin, deletion of chromosome 13, or hypodip-
oidy, may beneﬁt the most from this treatment ap-
roach [46-50]. Proceeding to tandem autologous-
nrelated HCT also may be beneﬁcial for patients
ith multiple myeloma who have not responded well
o conventional therapy. Moreover, our ﬁndings sug-
est that for patients with chemotherapy-refractory
isease or disease progression/relapse after autologous
CT, tandem autologous-unrelated HCT may offer a
ubstantial disease-free survival beneﬁt. Additional
ollow-up and treatment of increased numbers of pa-
ients in a prospective clinical trial are needed to
etermine whether long-term cures of multiple my-
loma can be achieved with this treatment approach.
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